炎症性肠病患者新冠疫苗接种的长期有效性与持久性
该前瞻性队列纳入1869例已接种新冠疫苗的成人炎症性肠病患者,随访超过1年。接种后43%发生新冠感染,但多为轻症,住院率低于1%;多数患者52周时仍可检出抗体,抗体水平与接种剂量正相关,抗TNF-α治疗则负相关。
要点
- 接种后43%发生新冠感染,但多为轻症,住院率低于1%。
- 高龄和使用糖皮质激素与接种后感染风险降低相关。
- 98%患者接种52周后仍可检出抗体,支持加强接种。
核心结论
- 新冠疫苗为绝大多数炎症性肠病成人提供有效且持久的保护,包括使用糖皮质激素者和老年人等脆弱人群。
- 炎症性肠病患者可从新冠疫苗加强接种中获益。
研究设计与样本
- 前瞻性队列研究,纳入1869例已接种新冠疫苗的成人炎症性肠病患者,随访超过1年。
- 分析接种后SARS-CoV-2感染相关因素,评估接种后12周抗体水平与后续感染的关系及保护阈值,并分析接种后52周抗体持久性相关因素。
主要发现
- 1869例参与者中43%在接种后发生新冠感染,但大多数感染为轻症,住院率低于1%。
- 与18-29岁相比,50-59岁者接种后感染风险降低(调整风险比0.57,95%CI 0.44-0.74)。
- 与未使用糖皮质激素者相比,使用者感染风险降低(调整风险比0.58,95%CI 0.39-0.87)。
- 98%的参与者在接种后52周仍可检出抗体水平。
- 接种后12周抗体水平和疫苗剂数与52周时更高抗体水平正相关,而抗TNF-α治疗呈负相关。
临床怎么用
- 应鼓励炎症性肠病患者完成新冠疫苗基础接种及加强接种。
- 对使用糖皮质激素、高龄等脆弱人群,疫苗接种仍可提供有效保护。
- 使用抗TNF-α治疗者抗体持久性可能较差,需关注加强接种策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: COVID-19 vaccination prevents severe disease in most patients with inflammatory bowel disease (IBD), but immunosuppressive medications can blunt serologic response. We followed adults with IBD for >1 year post-COVID-19 vaccination to describe factors associated with SARS-CoV-2 infection after vaccination, evaluate for a protective SARS-CoV-2 antibody level, characterize SARS-CoV-2 antibody persistence, and identify factors associated with humoral immune response durability. METHODS: Using a prospective cohort of COVID-19 immunized adults with IBD, we analyzed factors associated with SARS-CoV-2 infection after vaccination. We evaluated for an association between SARS-CoV-2 antibody level 12 weeks postvaccination and subsequent SARS-CoV-2 infection and assessed for a threshold of protection using receiver-operating characteristic curve analysis. We then conducted a separate analysis evaluating factors associated with persistence of SARS-CoV-2 antibodies 52 weeks postimmunization. RESULTS: Almost half (43%) of 1869 participants developed COVID-19 after vaccination, but most infections were mild, and <1% required hospitalization. Older age and corticosteroid use were associated with a decreased risk of SARS-CoV-2 infection postvaccination (50-59 years of age vs 18-29 years of age: adjusted hazard ratio, 0.57; 95% confidence interval, 0.44-0.74; steroid users vs nonusers: adjusted hazard ratio, 0.58; 95% confidence interval, 0.39-0.87). Most (98%) participants had detectable antibody levels at 52 weeks postvaccination. Antibody levels at 12 weeks and number of vaccine doses were positively associated with higher antibody levels at 52 weeks, while anti-tumor necrosis factor α therapy was negatively associated. CONCLUSIONS: COVID-19 vaccination generates an effective and durable protective response for the vast majority of adults with IBD, including vulnerable populations such as corticosteroid users and older individuals. Patients with IBD benefit from COVID-19 booster vaccination.
引用
- Brenner EJ, Weaver KN, Zhang X, et al. Long-Term Effectiveness and Durability of COVID-19 Vaccination Among Patients With Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2024. PMID: 38369224. doi:10.1016/j.cgh.2024.02.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。